Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.22 USD | +0.11% | -4.36% | +15.82% |
05-08 | Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating | MT |
05-07 | IDEAYA Biosciences Shares Fall After Q1 Loss | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.82% | 3.12B | |
+26.55% | 44.96B | |
+0.13% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+10.16% | 26.08B | |
-20.96% | 19.03B | |
+6.64% | 12.75B | |
+28.71% | 12.06B | |
-3.95% | 11.75B |
- Stock Market
- Equities
- IDYA Stock
- News IDEAYA Biosciences, Inc.
- IDEAYA Biosciences Initiates Phase 2 Expansion of Combination Therapy for Metastatic Cutaneous Melanoma